10-Q: Cannabist Co. Faces Deepening Losses, Going Concern Doubt

The Cannabist Company reported significant revenue declines and increased net losses, raising substantial doubt about its ability to continue as a going concern.

Summary

• The Cannabist Company Holdings Inc. (formerly Columbia Care Inc.) reported a net loss of $14.655 million for the three months ended September 30, 2025, a 731% increase from $1.763 million in the prior year period.
• For the nine months ended September 30, 2025, the net loss was $124.247 million, a 149% increase from $49.974 million in the same period last year.
• Revenues decreased by 30% for both the three-month and nine-month periods, falling to $79.912 million and $253.702 million, respectively, primarily due to divestitures and a net decline in existing operations.
• Gross profit declined by 48% for both periods, reaching $22.911 million for the three months and $69.349 million for the nine months.
• The company had negative operating cash flow of $35.666 million for the nine months ended September 30, 2025.
• As of September 30, 2025, cash and restricted cash stood at $20.896 million, with total debt obligations of $299.252 million.
• The company's accumulated deficit grew to $1,309.847 million as of September 30, 2025, from $1,185.501 million at December 31, 2024.
• A 2025 Debt Transaction was completed on May 29, 2025, exchanging existing senior notes for new 9.25% Senior Secured Notes due December 31, 2028, and 9.0% convertible notes, along with the issuance of 118,209,105 warrants.
• The company continues to divest non-core assets, including recent sales in Pennsylvania, California (Balboa, North Hollywood, DeSoto, THC), Milford Delaware, and Florida (license and cultivation facility).

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by substantial net losses, negative operating cash flow, declining revenues and gross profit, and an explicit 'going concern' warning. While debt restructuring provides some relief, the overall financial health is very poor, and the future is highly uncertain.

Positives

• The company completed a significant debt restructuring (2025 Debt Transaction) on May 29, 2025, extending maturity dates of senior notes to December 31, 2028, which provides some near-term liquidity relief.
• Divestitures of non-core assets generated cash proceeds, such as $13.957 million from business sales and $4.1 million from license sales during the nine months ended September 30, 2025.
• Operating expenses (SG&A) decreased by 29% for the three months and 26% for the nine months ended September 30, 2025, indicating some cost control efforts.
• Changes in regulation allowing for adult-use cannabis contributed to a revenue growth of $2.178 million for the three months and $1.463 million for the nine months ended September 30, 2025, in certain markets.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to significant net losses, negative operating cash flow, and limited cash reserves.
• Net loss increased by 731% to $14.655 million for the three months ended September 30, 2025, and by 149% to $124.247 million for the nine months ended September 30, 2025.
• Total revenues decreased by 30% for both the three-month ($34.871 million decrease) and nine-month ($108.882 million decrease) periods compared to the prior year.
• Gross profit decreased by 48% for both the three-month ($20.899 million decrease) and nine-month ($65.050 million decrease) periods.
• Loss from operations increased by 114% to $12.030 million for the three months and by 331% to $36.026 million for the nine months.
• Adjusted EBITDA decreased significantly, from $14.815 million to $3.041 million for the three months, and from $47.657 million to $19.817 million for the nine months.
• Cash and restricted cash declined from $37.930 million at December 31, 2024, to $20.896 million at September 30, 2025.
• Total equity is negative $152.949 million as of September 30, 2025, worsening from negative $30.059 million at December 31, 2024.
• An appeal is pending in the Ontario Court of Appeal regarding the 2025 Debt Transaction, scheduled for February 2026, which could challenge the restructuring.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, dependent on generating sufficient cash flow, asset divestitures, or external financing.
• The review of strategic alternatives (asset sales, mergers, other transactions) may not be successful, could create significant risks, and may not achieve intended benefits.
• Failure to obtain sufficient funding or complete strategic transactions on acceptable terms, or to negotiate with creditors, could force delays, scope reductions, asset liquidation, or cessation of operations.
• Covenants in debt agreements (2028 Notes and 2028 Convertible Notes) restrict operations, including incurring additional debt, paying dividends, making investments, and creating liens, which may inhibit business flexibility and strategic alternatives.
• Failure to comply with debt covenants could lead to acceleration of outstanding debt, potentially forcing bankruptcy, unfavorable asset sales, or other adverse actions.
• The cannabis industry remains illegal under U.S. federal law, posing ongoing legal, regulatory, and financial risks, including the impact of Section 280E of the Internal Revenue Code.
• The company's ability to retain or hire qualified personnel is uncertain due to challenging financial conditions in the industry and for the company.
• The volatility of the market price of the company's common shares is a risk factor.

Future Outlook

The company's continuation as a going concern depends on its ability to generate sufficient cash flow from operations, asset divestitures, or external financing. The Board has formed a Special Committee to review strategic alternatives, including potential asset sales, mergers, or other strategic or financial transactions, in light of ongoing operational and financial challenges and the uncertainty of U.S. federal regulatory changes, particularly regarding Section 280E taxation. There is no assurance that any transaction or strategy will be completed on favorable terms or at all, or that it will achieve its intended benefits.

Management Comments

• "The decrease in revenue... was driven by the net decline in revenue of $13,433 [thousand] in our existing retail and wholesale operations and a decline of $23,616 [thousand] from the sale or closure of certain operations. This was partly offset by changes in regulation allowing for adult use which contributed to a revenue growth of $2,178 [thousand] during the three months ended September 30, 2025, as compared to the prior period."
• "Our future financial results are subject to significant potential fluctuations caused by, among other things, growth of sales volume in new and existing markets and our ability to control operating expenses."
• "Our financial results may be impacted significantly by changes to the regulatory environment in which we operate, on a local, state, and federal level."

Industry Context

The company operates in a highly regulated and multi-jurisdictional cannabis industry in the U.S., which faces significant uncertainty due to federal illegality and the impact of Section 280E taxation. While some states are expanding to adult-use markets, providing some revenue growth opportunities, the overall industry environment presents operational and financial challenges. The company's strategy of divesting non-core assets and reviewing strategic alternatives reflects a broader trend among cannabis multi-state operators to optimize portfolios and improve financial health amidst a challenging capital market and regulatory landscape.

Corporate Governance

Legal Proceedings

• Murchinson Ltd. filed an application in the Ontario Superior Court of Justice (Commercial List) on March 27, 2025, opposing the 2025 Debt Transaction, claiming it was oppressive, breach of contract, and civil conspiracy. The court ruled in favor of the company on May 21, 2025.
• Murchinson Ltd. has filed an appeal to the Court of Appeal for Ontario, with a hearing scheduled in February 2026.

Stakeholder Impact

• Shareholders: Face significant risk of not receiving full value, or potentially no value, for their investment if the company is unable to continue as a going concern or complete strategic transactions on favorable terms. Potential for dilution from future capital raises or debt-to-equity conversions.
• Creditors: May not receive full value for their investment if the company cannot meet financial obligations. The company may need to negotiate concessions or waivers from creditors.
• Employees: Potential for loss of key personnel due to challenging financial conditions and uncertainty about the company's future.
• Suppliers: May face extended payment terms if the company's liquidity issues persist.
• Customers: Potential for disruption in services or product availability if operations are curtailed or cease.

Next Steps

• The Special Committee will continue to review strategic alternatives, including potential asset sales, mergers, or other strategic or financial transactions.
• The company needs to obtain sufficient funding or complete strategic transactions on acceptable terms to continue as a going concern.
• Negotiations with creditors for waivers and/or concessions may be necessary to permit asset divestitures or other actions.
• The appeal by Murchinson Ltd. regarding the 2025 Debt Transaction is scheduled for a hearing in February 2026.
• The company must maintain specified Consolidated Leverage Ratios as of each fiscal quarter-end commencing March 31, 2026, as per new debt covenants.

Key Dates

Recommendation

The company is in severe financial distress, explicitly stating 'substantial doubt as to our ability to continue as a going concern.' It has reported massive net losses, declining revenues and gross profits, negative operating cash flow, and a deeply negative equity position. While a debt restructuring was completed, it merely pushed out maturities, and the underlying business performance remains weak. The ongoing legal challenge to the debt restructuring and the highly uncertain outcome of the strategic review further compound the risks. Investors face a high probability of significant capital loss, making a 'strong sell' recommendation appropriate.

Keywords

Cannabis, Marijuana, Multi-state operator, SEC filing, 10-Q, Financial results, Net loss, Revenue decline, Going concern, Debt restructuring, Asset divestitures, Cannabist Company, CBSTF, OTC Markets, Cannabis regulation, Section 280E